109 results
Page 2 of 6
8-K
EX-99.1
09uvsbwx2yh51uns
9 Nov 22
BeiGene Reports Third Quarter 2022 Financial Results
7:06am
8-K
EX-99.1
gn5friee8cra039 ffrz
4 Aug 22
BeiGene Reports Second Quarter 2022 Financial Results
7:08am
8-K
EX-99.1
pevsgcv9 lgotoe
14 Jun 22
BeiGene Highlights Growing Portfolio and Pipeline Targeting Hematologic Malignancies at European Hematology Association 2022 Congress
5:16pm
8-K
EX-99.1
bvep84ib9 joj
27 May 22
BeiGene Clinical Data Presentations at 2022 ASCO Annual Meeting Demonstrate Mature and Growing Oncology Portfolio
8:33am
8-K
EX-99.1
qn47iany 1gkv
5 May 22
BeiGene Reports First Quarter 2022 Financial Results
7:06am
8-K
EX-10.1
somvd llmnluml
22 Feb 22
BRUKINSA was granted approval by the European Commission for the treatment of Waldenström’s macroglobulinemia in November 2021
4:10pm
8-K
EX-99.1
96jxw
2 Feb 22
Drs. Margaret Dugan and Alessandro Riva Appointed to BeiGene Board of Directors
4:12pm
8-K
EX-99.1
7kymp1
10 Jan 22
China NMPA Approves Tislelizumab as Second- or Third-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer
7:38am
8-K
EX-99.2
49tsv7x7gc5eiw8pbz
6 Dec 21
BeiGene Announces Pricing of its RMB22.2 billion (US$3.5 billion) Initial Public Offering on the STAR Market of the Shanghai Stock Exchange in China
4:16pm
424B5
y2116uwsn04ztt qptom
1 Dec 21
Prospectus supplement for primary offering
5:07pm
424B5
2ahmkhuibee5mw1a65
23 Nov 21
Prospectus supplement for primary offering
5:14pm
8-K
EX-99.1
ypka2fkbehqftkqfk
26 Aug 21
Other Events
4:19pm
8-K
EX-99.1
ac9vnmvrwi9yiqvawmw
5 Aug 21
BeiGene Reports Second Quarter 2021 Financial Results
4:48pm